Our highly skilled and dedicated research team is pleased to announce that we are currently recruiting patients for the following studies.
Regeneron: Designed for diabetic retinopathy patients by using intravitreal injection of a anti-VEGF product. To join the study, patients must
Have type 1 or type 2 diabetes mellitus
Be confirmed to have moderately severe to severe nonproliferative diabetic retinopathy
Roche: A Phase 2 study to evaluate an investigational product to treat patients with neovascularization secondary to AMD. To join the study, patients must be
Treatment-naive with subfoveal or juxtafoveal wet AMD (no prior treatment for CNV) with subfoveal fluid or hemorrhage.
Best corrected viasual acuity 20/50 to 20/320 (Inclusive) Snellen
For more information, please contact Dr. John Olson or Sherrie Cox:
800.255.7188
